If you have certain inflammatory conditions, your doctor might suggest Cimzia (certolizumab) as a treatment option for you.
Cimzia is a prescription medication thats used in adults to treat:
Cimzia is a type of drug called a tumor necrosis factor blocker. You receive it as an injection under your skin.
This article describes the dosages of Cimzia, including its forms, strength, and how to use the drug. To learn more about Cimzia, see this in-depth article.
Note: This article covers Cimzias typical dosages, which are provided by the drugs manufacturer. But when using Cimzia, always take the dosage that your doctor prescribes.
Cimzia is a medication that youll get as an injection under your skin. Your doctor may give you the injection in their office. Or they can teach you or your caregiver how to give yourself the injection at home.
Cimzia comes in two different forms:
Both forms of Cimzia contain one strength: 200 milligrams (mg).
Your Cimzia dosage will depend on the condition that youre treating. Other factors may include your body weight and how you respond to the treatment.
For most conditions, youll likely start treatment with a higher dose, called the starting dose or loading dose. This helps your body respond faster to the drug.
After a certain amount of time, your doctor may reduce your dose to what is called a maintenance dose. This is the dose that you take long term to keep your symptoms under control.
The information below describes dosages that are commonly used or recommended. But be sure to take the dosage your doctor prescribes for you. Your doctor will determine the best dosage to fit your needs.
For plaque psoriasis, the typical dosage of Cimzia is 400 mg (two injections of 200 mg) once every 2 weeks.
If you weigh less than or equal to 90 kilograms (about 198 pounds), your doctor might reduce your dosage. Specifically, after your first three doses, you may have a 200-mg dose (one injection) once every 2 weeks.
For rheumatoid arthritis and psoriatic arthritis, the typical starting dosage of Cimzia is 400 mg once every 2 weeks.
After three doses at 400 mg, your doctor may switch you to a maintenance dose. This is typically 200 mg, which youll receive once every 2 weeks.
In some cases, your doctor may change your maintenance dosage to 400 mg once every 4 weeks. This would reduce the number of injections you have per month. Do not switch to this dosage without talking with your doctor first.
Ankylosing spondylitis and non-radiographic axial spondyloarthritis are forms of arthritis that affect the spine. For these conditions, the typical starting dosage of Cimzia is 400 mg once every 2 weeks.
After three doses at 400 mg, your doctor may switch you to a maintenance dose. This is typically 200 mg, which youll receive once every 2 weeks. Or it may be 400 mg, received once every 4 weeks.
For Crohns disease, the typical starting dosage of Cimzia is 400 mg once every 2 weeks for three doses.
If your symptoms have eased after this, your doctor will switch you to a maintenance dosage. This will likely be 400 mg once every 4 weeks.
Yes, Cimzia is typically used as a long-term treatment. If you and your doctor determine that Cimzia is safe and effective for you, its likely that youll use it long term.
Here are the answers to some frequently asked questions about Cimzias dosage.
The Food and Drug Administration (FDA) hasnt approved Cimzia to treat ulcerative colitis (a type of inflammatory bowel disease). But Cimzia is being studied to see if it could be effective for this use.
Because Cimzia isnt approved to treat ulcerative colitis, there isnt a recommended dosage for this condition. If youre interested in taking Cimzia to treat ulcerative colitis, talk with your doctor. This would be an off-label use of the drug. (Off-label drug use means using a drug for a purpose other than that approved by the FDA.)
It may take a few weeks before your symptoms start to ease. If you think Cimzia isnt working for you, dont change the dosage of Cimzia that your doctor has prescribed. Talk with your doctor if you have questions about whether Cimzia is working for you.
If you miss an appointment to have an injection of Cimzia, call your doctors office right away to reschedule.
If you usually inject Cimzia yourself and you miss a dose, call your doctors office to find out what to do. They may tell you to take the missed dose as soon as possible. But if its nearly time for your next dose, they may tell you to skip the missed dose.
Your doctor can also tell you if you need to adjust your dosing schedule after a missed dose.
If you need help remembering to take your dose of Cimzia on time, try using a medication reminder. This can include setting an alarm, downloading a reminder app, or setting a timer on your phone. It can also be helpful to write your Cimzia dosing schedule on a calendar.
The dosage of Cimzia youre prescribed may depend on:
If you have any questions about the dosage of Cimzia you should take, talk with your doctor.
Youll receive Cimzia as an injection under your skin. Your doctor can give you Cimzia injections in their office. They can also teach you or your caregiver how to do this at home using Cimzia prefilled syringes.
Youll take Cimzia either once every 2 weeks or once every 4 weeks. And you may need to take one or two injections each time. Always follow your doctors instructions.
You can inject Cimzia into these areas of your body:
Each time you give yourself Cimzia, you should rotate injection sites. This means injecting the drug into a different place in one of the areas mentioned above. Make a note of the date and the area you used for each injection. This way you can avoid injecting in the same place next time.
If you need to take two injections for your dose, the injections should be at least 2.5 centimeters (about 1 inch) apart.
Avoid injecting Cimzia into areas of skin that are tender, red, discolored, bruised, or hard. Also avoid areas where you have scars or stretch marks.
Dont use more Cimzia than your doctor prescribes. Using more than this can lead to serious side effects.
Call your doctor right away if you think youve used too much Cimzia. You can also call 800-222-1222 to reach the American Association of Poison Control Centers, or use its online resource. But if you have severe symptoms, call 911 or your local emergency number immediately, or go to the nearest emergency room.
The sections above describe the typical dosages provided by the drug manufacturer. If your doctor recommends Cimzia for you, they will prescribe the dosage thats right for you.
Remember, you shouldnt change your dosage of Cimzia without your doctors recommendation. Only take Cimzia exactly as prescribed. Talk with your doctor if you have questions or concerns about your current dosage.
Here are some questions you may want to ask your doctor:
You can learn more about the conditions Cimzia treats by subscribing to Healthlines newsletters for psoriasis, inflammatory bowel disease (IBD), and rheumatoid arthritis.
Disclaimer: Healthline has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.
Read more:
Cimzia and Dosage: Strength, Forms, When to Use, and More - Healthline
- Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment ... - Dermatology Times - April 18th, 2024 [April 18th, 2024]
- Psoriasis Patients with Arthralgia At Increased Risk of Psoriatic Arthritis Development - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Diagnosing Psoriatic Arthritis for the Dermatologist: Guidance From the Experts - Medscape - April 18th, 2024 [April 18th, 2024]
- Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg - MD Magazine - April 18th, 2024 [April 18th, 2024]
- The Impact of Pediatric Plaque Psoriasis on Children and Caregivers - HMP Global Learning Network - April 18th, 2024 [April 18th, 2024]
- Guselkumab Led to Improvements Over Several Psoriatic Arthritis Disease Domains - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Dual Diagnosing and Managing Psoriasis and Psoriatic Arthritis - The Dermatologist - April 18th, 2024 [April 18th, 2024]
- Etanercept Effective for Psoriasis, Rheumatic Disease Among Patients Extending Treatment After 12-Weeks - MD Magazine - February 9th, 2024 [February 9th, 2024]
- High Response Rates in Psoriasis With Oral IL-23 Inhibitor - Medpage Today - February 9th, 2024 [February 9th, 2024]
- Psoriasis and eczema have complex causes and consequences that researchers are seeking to uncover - Medical Xpress - February 9th, 2024 [February 9th, 2024]
- New Hope in Treatment of Plaque Psoriasis: Study Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- No Difference in Psoriasis Immune Response Despite Switch Between AVT02, Adalimumab - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Oral IL-23 Receptor Antagonist Peptide Effective in PASI Reduction for Psoriasis - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Breakthrough in Psoriasis Treatment: JNJ-77242113 Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from Phase II Trial of Oral Interleukin Inhibitor for Psoriasis Treatment - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from the FRONTIER 1 Trial - An Exploration of JNJ-77242113 in the Treatment of Moderate-to ... - Medriva - February 9th, 2024 [February 9th, 2024]
- Personal Experience with Psoriatic Arthritis and Atopic Dermatitis - Medriva - February 9th, 2024 [February 9th, 2024]
- Rising Cost of Stelara: Impact on Patients and Johnson & Johnson's Market Performance - Medriva - February 9th, 2024 [February 9th, 2024]
- Global Psoriatic Arthritis (PsA) Treatment Market to achieve a remarkable US$ 15.6 Billion by 2028, - PharmiWeb.com - February 9th, 2024 [February 9th, 2024]
- Tremfya potential highlighted by industry analyst GlobalData - The Pharma Letter - May 31st, 2023 [May 31st, 2023]
- Stress Leads to Increased Risk of Depression, Anxiety for Psoriasis ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Janssen Announces Positive Results From Guselkumab Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Early Intervention with Secukinumab May Be Effective for Patients ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Scratching the itch, Lynk Pharmaceuticals trialling ointment for ... - OutSourcing-Pharma.com - May 31st, 2023 [May 31st, 2023]
- Brepocitinib More Efficacious Than Placebo in Long-Term Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- For Patients With Birthmarks, Psychosocial Interventions Improved ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Robert Hariri, MD: Natural Killer Cell Therapy Shows Remarkable ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Nalbuphine ER Tablets Show Promise as Cough Therapy in ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Benefit of Empagliflozin in HFpEF Consistent Regardless of Diuretic ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- selectION reports results from SAD stage of si-544 Phase Ib trial - Clinical Trials Arena - May 31st, 2023 [May 31st, 2023]
- No Link Observed Between Gastrointestinal Tract Surgery and New ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Lynk doses first cohort in Phase Ib trial of psoriasis therapy - Clinical Trials Arena - May 30th, 2023 [May 30th, 2023]
- Metabolic Inflammation Contributes to Depression in Psoriatic Disease - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Encouraging Diversity and Inclusion for Patients With Psoriatic ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- The Weekly Roundup: May 22-26 - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Pediatric Psoriasis Market: A Study of the Industry's Key Applications ... - The Navajo Post - May 30th, 2023 [May 30th, 2023]
- Phototherapy Lamps Market are set to witness a CAGR of 5.8 ... - Digital Journal - May 30th, 2023 [May 30th, 2023]
- Celltrion seeks approval for Stelara biosimilar in EU - The Investor - May 30th, 2023 [May 30th, 2023]
- Peter Marinkovich, MD: FDA Approval of B-VEC Gene Therapy for ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Nick Stucky, MD, Phd: Implications for Media Influence on Minoxidil ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Tildrakizumab Linked With HRQOL Improvement in Psoriasis in a Real-World Setting - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Clinical Utility of Deucravacitinib for the Management of Moderate to ... - Dove Medical Press - May 18th, 2023 [May 18th, 2023]
- Covid-19 and Psoriasis: Is there a link? - Dunya News - May 18th, 2023 [May 18th, 2023]
- Improvement Needed in Study Interventions to Better Skin Self ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data - Marketscreener.com - May 18th, 2023 [May 18th, 2023]
- Adam Friedman, MD: Addressing Disparities in Care for Patients ... - MD Magazine - May 18th, 2023 [May 18th, 2023]
- Early-Infancy Meningitis Infection Linked With Increased Risk of ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- NOVN: Counting Down to PDUFA - Yahoo Finance - May 18th, 2023 [May 18th, 2023]
- Psoriatic Arthritis (PsA) Treatment Market is likely to register CAGR ... - Future Market Insights - May 18th, 2023 [May 18th, 2023]
- New campaign raises awareness of topical steroid withdrawal - Professional Beauty - May 18th, 2023 [May 18th, 2023]
- MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody sonelokimab in... - February 2nd, 2023 [February 2nd, 2023]
- EVELO BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events (form 8-K) -... - February 2nd, 2023 [February 2nd, 2023]
- 12 Ways to Treat Psoriasis at Home - Healthline - January 22nd, 2023 [January 22nd, 2023]
- DTC Advertising Of Prescription Drugs In The U.S. Often Promotes Products With Comparatively Low Therapeutic Value - Forbes - January 19th, 2023 [January 19th, 2023]
- Types of Psoriasis: Pictures, Symptoms and Treatments - Healthline - December 18th, 2022 [December 18th, 2022]
- Psoriasis Pathogenesis and Treatment - PMC - PubMed Central (PMC) - November 23rd, 2022 [November 23rd, 2022]
- Drug-Provoked Psoriasis: Is It Drug Induced or Drug Aggravated? - November 23rd, 2022 [November 23rd, 2022]
- Im a Dermatologist and These 7 Things Could Be Making Your Psoriasis Worse - Well+Good - October 19th, 2022 [October 19th, 2022]
- 'Worst time of the year for me to be covered in scabs': Amber Heard's Alleged Ex Cara Delevingne Revealed Her Psoriasis Struggle Made Kate Moss Scream... - October 19th, 2022 [October 19th, 2022]
- Psoriasis: What It Is, Symptoms, Causes, Types & Treatment - October 17th, 2022 [October 17th, 2022]
- What is psoriasis and which foods ease symptoms? - Evening Standard - October 17th, 2022 [October 17th, 2022]
- Chronic inflammatory diseases: what they are - Emergency Live International - October 17th, 2022 [October 17th, 2022]
- How remote care can deliver a step change in treatment for inflammatory skin conditions - PoliticsHome - October 17th, 2022 [October 17th, 2022]
- Probiotics Supplementation may Improve Symptoms of Hyperuricemia and Gout - Rheumatology Network - October 15th, 2022 [October 15th, 2022]
- Psoriasis Pathogenesis and Treatment - PubMed - October 2nd, 2022 [October 2nd, 2022]
- Best and Worst Drinks for Psoriasis - Everyday Health - October 2nd, 2022 [October 2nd, 2022]
- These Are the 10 Most Common Chronic Skin Conditionsand the Most Important Facts to Know About Them - Parade Magazine - October 2nd, 2022 [October 2nd, 2022]
- Survey Addresses Concerns Regarding Reproductive Healthcare Communication in Women with RA, PsA - Rheumatology Network - October 2nd, 2022 [October 2nd, 2022]
- Psoriasis Types, Symptoms & Causes | NIAMS - September 29th, 2022 [September 29th, 2022]
- What Is Psoriasis And Can It Be Treated? - Forbes - September 29th, 2022 [September 29th, 2022]
- Plaque Psoriasis Treated With Tildrakizumab Shown to be Effective in Real-World Settings - MD Magazine - September 29th, 2022 [September 29th, 2022]
- Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis - Business Wire - September 29th, 2022 [September 29th, 2022]
- 15 Items That Will Make Your Life With Psoriatic Arthritis Easier - BlackDoctor.Org - September 29th, 2022 [September 29th, 2022]
- Types of Psoriasis and Their Effects on the Immune System - Cureus - September 27th, 2022 [September 27th, 2022]
- MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody sonelokimab in patients with active psoriatic arthritis - BioSpace - September 27th, 2022 [September 27th, 2022]
- How diversity and inclusion continues to be incorporated in dermatology - PMLiVE - September 27th, 2022 [September 27th, 2022]
- Arcutis Announces Topline Results From ARRECTOR Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Scalp A - Benzinga - September 27th, 2022 [September 27th, 2022]
- Psoriasis Treatment Market Size to Hit USD 51.24 Bn by 2030 - GlobeNewswire - August 15th, 2022 [August 15th, 2022]
- Ventyx Sees Initiation Of Mid-Stage Psoriasis Study In Q4 2022 Following Positive Data From Initial-Stage - Benzinga - August 15th, 2022 [August 15th, 2022]